Atossa Therapeutics (NASDAQ: ATOS) stock recorded a new high for the year a few days ago. In fact, the stock continued to grow since the company released its first quarter 2021 financial results on May 14th. The reason investors were so excited is the company has made great progress on its two key development programs.
The oral Endoxifen is one of its two key development drugs, which is used for the treatment of breast cancer. Recently, the company announced the final data from its Phase 2 clinical study of oral Endoxifen. A statistically significant reduction of about 74% in tumor cell proliferation was achieved over the 22 days of dosing. Proliferation was measured by Ki-67, a recognized standard measurement of breast cancer cell proliferation.
The company said that it has begun the formal non-clinical toxicology program that will be needed for a NDA to seek marketing approval for Endoxifen and plans to apply to the U.S. FDA for approval to conduct a clinical study in the United States as soon as possible.
In addition, AT-301 administered by nasal spray, another key program of the company, is being developed for at home use for patients recently diagnosed with COVID-19. AT-301 was considered to be safe and well tolerated in healthy male and female participants in its phase 1 study at two different dose levels over 14 days. And now, this program has entered the phase 2 study.
This year, ATOS stock has increased by nearly 400% so far. The stock is easy to rally to $10 or more if the company succeeds in its two key programs. Therefore, the stock is worth watching for a long period of time.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.